Analysts See $-0.16 EPS for Synergy Pharmaceuticals Inc. (SGYP) on May, 9

April 17, 2018 - By Elizabeth Jones

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Corporate Logo
Big Money Sentiment decreased to 1.22 in 2017 Q4. It has change of 0.68, from 2017Q3’s 1.9. The ratio worsened due to Synergy Pharmaceuticals Inc. positioning: 21 sold and 34 reduced. 24 funds took holdings and 43 increased holdings. Investors holded 147.06 million in 2017Q3 but now own 125.65 million shares or 14.56% less.
Fny Managed Accounts Lc has invested 0% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Morgan Stanley holds 1.38M shs. Signaturefd Ltd Limited Liability Company, a Georgia-based fund reported 10,000 shs. Natl Bank Of Montreal Can accumulated 0% or 63,853 shs. Pnc Grp Inc owns 2,860 shs. Blackrock owns 22.00 million shs for 0% of their capital. Wells Fargo & Mn has 163,657 shs for 0% of their capital. Da Davidson Communications has 141,053 shs for 0.01% of their capital. State Street invested in 0% or 20.45M shs. Millennium Mngmt Limited Liability Corporation holds 0% of its capital in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 18,825 shs. United Kingdom-based Gsa Ptnrs Limited Liability Partnership has invested 0.01% in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP). Barclays Pcl holds 0% or 54,444 shs. Hsbc Hldgs Pcl owns 23,742 shs for 0% of their capital. Janney Montgomery Scott Limited Co owns 0% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 31,000 shs. Moreover, America First Investment Advsrs Ltd has 0.05% invested in Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) for 62,947 shs.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP)’s earnings report is awaited On May, 9., as reported by RTT. Analysts have anticipation on stock’s earnings per share of $-0.16. That’s up 46.67 % from last year’s $-0.3 earnings per share. -11.11 % EPS growth is what Wall Street’s predicts after $-0.18 reported EPS last quarter. SGYP reached $1.77 on during the last trading session after $0.04 change.Currently Synergy Pharmaceuticals Inc. is downtrending after 62.55% change in last April 17, 2017. SGYP has also 1.97 million shares volume. SGYP underperformed the S&P500 by 74.10%.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Ratings Coverage

Total analysts of 5 have positions in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) as follows: 4 rated it a “Buy”, 0 with “Sell” and 1 with “Hold”. The positive are 80%. Since October 18, 2017 according to StockzIntelligence Inc Synergy Pharmaceuticals Inc has 14 analyst reports. In Friday, January 26 report BTIG Research maintained it with “Buy” rating and $7.0 target. On Thursday, November 9 the rating was maintained by Cantor Fitzgerald with “Buy”. On Friday, November 10 the firm has “Buy” rating given by Canaccord Genuity. On Thursday, January 25 the company was maintained by Canaccord Genuity. The company rating was maintained by H.C. Wainwright on Monday, January 8. On Wednesday, October 18 the stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by H.C. Wainwright. On Friday, January 5 the firm earned “Perform” rating by Oppenheimer. On Thursday, January 25 the stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) earned “Buy” rating by Cantor Fitzgerald. On Tuesday, March 6 the stock of Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) has “Buy” rating given by Cantor Fitzgerald. On Monday, March 5 the firm has “Buy” rating by H.C. Wainwright given.

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders.The company has $436.59 million market cap. The Company’s lead product is plecanatide, a novel uroguanylin analog that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.Currently it has negative earnings. The firm also develops dolcanatide to treat mild-to-moderate ulcerative colitis.

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.